BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36572280)

  • 1. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials.
    Diefenhardt M; Fleischmann M; Martin D; Hofheinz RD; Piso P; Germer CT; Hambsch P; Grützmann R; Kirste S; Schlenska-Lange A; Ghadimi M; Rödel C; Fokas E;
    Radiother Oncol; 2023 Feb; 179():109455. PubMed ID: 36572280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
    Hofheinz RD; Arnold D; Fokas E; Kaufmann M; Hothorn T; Folprecht G; Fietkau R; Hohenberger W; Ghadimi M; Liersch T; Grabenbauer GG; Sauer R; Rödel C; Graeven U;
    Ann Oncol; 2018 Aug; 29(8):1793-1799. PubMed ID: 29873684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.
    Fokas E; Schlenska-Lange A; Polat B; Klautke G; Grabenbauer GG; Fietkau R; Kuhnt T; Staib L; Brunner T; Grosu AL; Kirste S; Jacobasch L; Allgäuer M; Flentje M; Germer CT; Grützmann R; Hildebrandt G; Schwarzbach M; Bechstein WO; Sülberg H; Friede T; Gaedcke J; Ghadimi M; Hofheinz RD; Rödel C;
    JAMA Oncol; 2022 Jan; 8(1):e215445. PubMed ID: 34792531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
    Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Rödel C; Fokas E
    JAMA Oncol; 2020 Sep; 6(9):1416-1421. PubMed ID: 32644104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.
    Fokas E; Fietkau R; Hartmann A; Hohenberger W; Grützmann R; Ghadimi M; Liersch T; Ströbel P; Grabenbauer GG; Graeven U; Hofheinz RD; Köhne CH; Wittekind C; Sauer R; Kaufmann M; Hothorn T; Rödel C;
    Ann Oncol; 2018 Jul; 29(7):1521-1527. PubMed ID: 29718095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
    Sauer R; Liersch T; Merkel S; Fietkau R; Hohenberger W; Hess C; Becker H; Raab HR; Villanueva MT; Witzigmann H; Wittekind C; Beissbarth T; Rödel C
    J Clin Oncol; 2012 Jun; 30(16):1926-33. PubMed ID: 22529255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
    Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
    BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.
    Fokas E; Allgäuer M; Polat B; Klautke G; Grabenbauer GG; Fietkau R; Kuhnt T; Staib L; Brunner T; Grosu AL; Schmiegel W; Jacobasch L; Weitz J; Folprecht G; Schlenska-Lange A; Flentje M; Germer CT; Grützmann R; Schwarzbach M; Paolucci V; Bechstein WO; Friede T; Ghadimi M; Hofheinz RD; Rödel C;
    J Clin Oncol; 2019 Dec; 37(34):3212-3222. PubMed ID: 31150315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials.
    von den Grün JM; Hartmann A; Fietkau R; Ghadimi M; Liersch T; Hohenberger W; Weitz J; Sauer R; Wittekind C; Ströbel P; Rödel C; Fokas E;
    Radiother Oncol; 2018 Sep; 128(3):557-563. PubMed ID: 29929861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited.
    Diefenhardt M; Schlenska-Lange A; Kuhnt T; Kirste S; Piso P; Bechstein WO; Hildebrandt G; Ghadimi M; Hofheinz RD; Rödel C; Fokas E;
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
    Kitz J; Fokas E; Beissbarth T; Ströbel P; Wittekind C; Hartmann A; Rüschoff J; Papadopoulos T; Rösler E; Ortloff-Kittredge P; Kania U; Schlitt H; Link KH; Bechstein W; Raab HR; Staib L; Germer CT; Liersch T; Sauer R; Rödel C; Ghadimi M; Hohenberger W;
    JAMA Surg; 2018 Aug; 153(8):e181607. PubMed ID: 29874375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94).
    Sauer R; Fietkau R; Wittekind C; Martus P; Rödel C; Hohenberger W; Jatzko G; Sabitzer H; Karstens JH; Becker H; Hess C; Raab R
    Strahlenther Onkol; 2001 Apr; 177(4):173-81. PubMed ID: 11370551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensified Total Neoadjuvant Therapy
    DE Felice F; Musio D; Iafrate F; Caponnetto S; Picone V; D'Ambrosio G; Magliocca FM; Tozzi F; DE Toma G; Tombolini V; Cortesi E
    Anticancer Res; 2022 Feb; 42(2):991-1000. PubMed ID: 35093899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall Survival After Treatment Failure Among Patients With Rectal Cancer.
    Diefenhardt M; Martin D; Fleischmann M; Hofheinz RD; Ghadimi M; Rödel C; Fokas E
    JAMA Netw Open; 2023 Oct; 6(10):e2340256. PubMed ID: 37902752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94.
    Sauer R; Fietkau R; Wittekind C; Rödel C; Martus P; Hohenberger W; Tschmelitsch J; Sabitzer H; Karstens JH; Becker H; Hess C; Raab R;
    Colorectal Dis; 2003 Sep; 5(5):406-15. PubMed ID: 12925071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial.
    Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Fleischmann M; Fokas E; Rödel C
    Radiother Oncol; 2021 Nov; 164():223-231. PubMed ID: 34619239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial.
    Kosmala R; Fokas E; Flentje M; Sauer R; Liersch T; Graeven U; Fietkau R; Hohenberger W; Arnold D; Hofheinz RD; Ghadimi M; Ströbel P; Staib L; Grabenbauer GG; Folprecht G; Kirste S; Uter W; Gall C; Rödel C; Polat B;
    Eur J Cancer; 2021 Feb; 144():281-290. PubMed ID: 33383348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.